HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

May 12, 2026 - 02:54

Halozyme Therapeutics announced its financial results for the first quarter of 2026 on Tuesday, posting a 42 percent year-over-year increase in total revenue to $377 million. The company also confirmed its financial guidance for the full year, signaling steady confidence in its operational trajectory.

Alongside the earnings report, Halozyme revealed a new $1 billion share repurchase program. The company projects it will buy back at least $400 million of its own shares during 2026, a move that typically signals management's belief that the stock is undervalued and a commitment to returning capital to shareholders.

Revenue growth was driven primarily by royalty payments from the company's drug delivery technology, which is used in several partner products. Halozyme's ENHANZE platform, a recombinant hyaluronidase enzyme, allows for subcutaneous injection of biologics that would otherwise require intravenous infusion. This technology has been licensed to major pharmaceutical partners, generating consistent royalty streams.

The company did not provide specific net income figures in the initial release but emphasized that operational cash flow remains strong enough to support both the buyback program and ongoing business investments. Halozyme also reiterated that its 2026 financial guidance remains unchanged, suggesting that management sees no immediate headwinds to its projected performance.

Halozyme's stock saw modest movement in after-hours trading following the announcement, as investors weighed the strong revenue growth against broader market conditions. The company continues to focus on expanding its technology partnerships and advancing its own pipeline of enzyme-based therapies.